|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Development and characterization of a microfluidic glucose sensing system based on an enzymatic microreactor and chemiluminescence detection显示文摘Chemiluminescence detection was developed as an alternative to amperometric detection for glucose analysis in a portable, microfluidics-based continuous glucose monitoring system. Amperometric detection allows easy determination of hydrogen peroxide, a product of the glucose oxidase-catalyzed reaction of glucose with oxygen, by oxidation at a microelectrode. However, (micro)electrodes in direct contact with physiological sample are subject to electrode fouling, which leads to signal drift, decreased reproducibility and shortened detector lifetimes. Moreover, there are a few species present in the body (e.g. ascorbic acid, uric acid) which can undergo oxidation at the same applied potential as hydrogen peroxide. These species can thus interfere with the glucose measurement, reducing detection specificity. The rationale for exploring chemiluminescence as opposed to amperometric detection is thus to attempt to improve the lifetime and reproducibility of glucose analysis for monitoring purposes, while reducing interference caused by other chemicals in the body. The study reported here represents a first step in this direction, namely the realization of a microfluidic device with integrated silicon photodiode for chemiluminescence detection of glucose. This microflow device uses a chaotic mixing approach to perform enzymatic conversion of glucose, followed by reaction of the hydrogen peroxide produced with luminol to produce light at 425 nm. The chemiluminescence reaction is catalyzed by horseradish peroxidase in the presence of iodophenol. The performance of the fabricated chip was characterized to establish optimal reaction conditions with respect to sample and reagent flow rates, pH, and concentrations. A linear calibration curve was obtained for current response as a function of glucose concentration in the clinically relevant range between 2 and 10 mM, with a sensitivity of 39 pA/mM (R = 0.9963, one device, n = 3) and a limit of detection of 230 μM (S/N = 3). | MOON B.-U. de VRIES M.G. WESTERINK B.H.C. VERPOORTE E. | 2012 | Science China Chemistry2012，55，4： | 2 |
| 2 | WNT and beta-catenin signalling:diseases and therapies显示文摘 | Moon RT Kohn AD De FerrariG V | 2004 | Nat Rev Genet2004，5，9： | 1 |
| 3 | WNT and betacatenin signalling:diseases and therapies显示文摘 | Moon R T Kohn A D De Ferrari G V | 2004 | Nature Reviews Genetics2004，5，9： | 1 |
| 4 | Development of a risk tool for deliberate self-extubation in intensive care patients显示文摘 | Moons P Sels K De Becker W | 2004 | Intensive Care Med2004，30，7： | 1 |
| 5 | Development of a risk assessment tool for deliberate self-extubation in intensive care patients显示文摘 | Moons P Sels K De Becker W | | 0，，07： | 1 |
| 6 | Schwann cellss for spinal cord repair显示文摘 | Oudega M Moon LD de Almeida Leme RJ | | 0，，06： | 1 |
| 7 | Wnt and beta-catenin signalling:diseases and therapies显示文摘 | Moon RT Kohn AD De Ferrari GV | 2004 | Nat Rev Genet2004，5，9： | 1 |
| 8 | The ups and downs of Wnt signaling in prevalent neurological disorders 显示文摘 | De Ferrari GV Moon RT | 2006 | Oncogene2006，25，57： | 1 |
| 9 | Role of placental growth factor (PLGF) in wound healing after glaucoma filtration surgery 显示文摘 | VAN BT VAN DE VEIRE S VANDEWALLE E MOONS L STAL- MANS I | 2011 | Bull Soc Beige Ophtalmo12011，，317： | 1 |
| 10 | Schwann cells for spinal cord repair显示文摘 | Oudega M Moon LD de Almeida Leme RJ | | 0，，06： | 1 |
| 11 | Use of terazosin in prostatodynia and validation of a symptom score questionnaire显示文摘 | Neal DE Moon TD | 1994 | Urology1994，43，4： | 1 |
| 12 | Introducing ad- vanced practice nurses/nurse practitioners in health care systems: a framework for reflection and analysis 显示文摘 | De Geest S Moons P Callens B | 2008 | Swiss Med Wkly2008，138，4344： | 1 |
| 13 | Development of a risk tool for deliberate self-extubation in intensive care patients显示文摘 | Moons P Sels K De Becker W | 2004 | Intensive Care Medicine2004，30，7： | 1 |
| 14 | Development of a risk assessment tool fol Deliberate self-extubation in intensive care patients显示文摘 | Moons P Sels K De Becker W | 2004 | Intensive Care Med2004，30，7： | 1 |
| 15 | Development of a risk tool for deliberate self- extubation in intensive carepatients显示文摘 | Moons P Sels K De Becket W | 2004 | Inten- sive Care Med2004，30，7： | 1 |
| 16 | Epidural naloxone reduces intestinal hypomotility but not analgesia of epidural morphine显示文摘 | Shim JY Choi JH Kim ES Kwon OK Moon DE | 2001 | Can J Anaesth2001，48，1： | 1 |
| 17 | Development of a risk tool for deliberate self--extubation in internsive care patients 显示文摘 | Moons P Sels K De Becker W | 2004 | Intensive care medicine2004，30，： | 1 |
| 18 | Development of a risk tool for deliberate self- extubation in intensive care patients 显示文摘 | Moons P Sels K De Becker W | 2004 | Intensive Care Med2004，30，7： | 1 |
| 19 | Development of a risk tool for de- liberatese'-extubation in intensive care patiens 显示文摘 | Moons P Sels K De Becker W | 2004 | Intensive Care Med2004，30，7： | 1 |
| 20 | WNT and betacatenin signalling: diseases and therapies显示文摘 | Moon RT Kohn AD De Ferrari GV | 2004 | Nat Rev Genet2004，5，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员